Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings briefing transcriptFiscal year ending March 2026, full year11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Gross Profit MarginExpected to improve by 6.4 percentage points under the plan for the fiscal year ending March 2027. The specific margin and year-on-year actual results are not disclosed
Operating profit marginSpecific target and actual figures are not disclosed
Selling, general and administrative expensesThe SG&A expense ratio is expected to increase by 5.3% under the plan for the fiscal year ending March 2027. The amount is not disclosed
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- The business segment names will change from “Health Screening Solutions Business” and “Health Management Cloud Business” to “Solutions Business” and “Cloud Business”
- Market size and share, competitors, and future management policy
- Numerical targets for the medium-term management plan have not been disclosed at this time
- A new plan is scheduled for release in the second quarter of the fiscal year ending March 2027
- The plan incorporates the assumption that cancellations resulting from the price revision will remain limited, and no customer attrition has occurred at this time
- The improvement in gross margin will come from the cumulative effects of the price revision, a higher cloud mix, new plans, and reductions in outsourcing costs through AI
- Policies regarding recruitment, M&A, the use of health data, dividends, and market changes
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The forecast assumes that cancellations resulting from the Growbase price revision will remain limited. The price revision, new plans and services, and reductions in outsourcing costs through AI are expected to contribute incrementally toward the second half of the fiscal yearNew initiatives
- Evolving Growbase into a platform centered on the collection, visualization and utilization of wellbeing data
- New plans, including Growbase Mentally, are scheduled for release in the second quarter of the fiscal year ending March 2027
- Improving the efficiency of the process for digitizing health screening results data through the use of AI
- Expanding channels into the mid-sized and small-business market
- Considering the continued use and portability of individual-level health data
Key KPIsA metric the company considers important as a management benchmark.
- Number of health screening service usersApproximately 400,000
- Number of Growbase IDsSlightly over approximately 1.8 million
- Paid leave utilization rate92 %
- Regular health checkup participation rate100 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The market for health screening service users is approximately 5–6 million people, compared with approximately 400,000 users for the company. The Growbase addressable market comprises approximately 16 million employees, while the company has slightly over approximately 1.8 million IDs. The company plans to increase prices and average customer spend, but actual figures are not disclosedMedium-term management plan targets
Specific numerical targets have not been disclosed at this timeFinancial targets
Specific targets, including the operating margin, have not been disclosedMarket Size / Share
- Administrative outsourcing services for health screenings, comprehensive medical checkups and related servicesApproximately 5–6 million people annuallyCompany shareApproximately 7–8%
- The Growbase market serving people employed by companies with more than 1,000 employeesApproximately 16 million peopleCompany shareSlightly over 10%
Number of employees
Not disclosed. The company is strengthening recruitment, primarily of highly skilled personnel, but the number of employees is not disclosedAnnual Dividend
The basic policy is to pay a single year-end dividend. The dividend amount is not disclosedPayout ratio
Not disclosed. The company emphasizes a balance between stable progressive dividends and growth investment| Item | Details |
|---|---|
| Document type | Earnings briefing transcript |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Gross Profit Margin | Expected to improve by 6.4 percentage points under the plan for the fiscal year ending March 2027. The specific margin and year-on-year actual results are not disclosed |
| Operating profit margin | Specific target and actual figures are not disclosed |
| Selling, general and administrative expenses | The SG&A expense ratio is expected to increase by 5.3% under the plan for the fiscal year ending March 2027. The amount is not disclosed |
| Key KPIs | Indicator name Number of health screening service users / Value Approximately 400,000 / Year on year against the same period last year Not disclosed, Indicator name Number of Growbase IDs / Value Slightly over approximately 1.8 million / Year on year against the same period last year Not disclosed, Indicator name Paid leave utilization rate / Value 92 % / Year on year against the same period last year Not disclosed, Indicator name Regular health checkup participation rate / Value 100 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | The market for health screening service users is approximately 5–6 million people, compared with approximately 400,000 users for the company. The Growbase addressable market comprises approximately 16 million employees, while the company has slightly over approximately 1.8 million IDs. The company plans to increase prices and average customer spend, but actual figures are not disclosed |
| Number of employees | Not disclosed. The company is strengthening recruitment, primarily of highly skilled personnel, but the number of employees is not disclosed |
| Assumptions Underlying the Business Outlook | The forecast assumes that cancellations resulting from the Growbase price revision will remain limited. The price revision, new plans and services, and reductions in outsourcing costs through AI are expected to contribute incrementally toward the second half of the fiscal year |
| Medium-term management plan targets | Specific numerical targets have not been disclosed at this time |
| Financial targets | Specific targets, including the operating margin, have not been disclosed |
| Annual Dividend | The basic policy is to pay a single year-end dividend. The dividend amount is not disclosed |
| Payout ratio | Not disclosed. The company emphasizes a balance between stable progressive dividends and growth investment |
| Market Size / Share | Market Administrative outsourcing services for health screenings, comprehensive medical checkups and related services / Market Size Approximately 5–6 million people annually / Company share Approximately 7–8%, Market The Growbase market serving people employed by companies with more than 1,000 employees / Market Size Approximately 16 million people / Company share Slightly over 10% |
| Key points of the Q&A | The business segment names will change from “Health Screening Solutions Business” and “Health Management Cloud Business” to “Solutions Business” and “Cloud Business”, Market size and share, competitors, and future management policy, Numerical targets for the medium-term management plan have not been disclosed at this time, A new plan is scheduled for release in the second quarter of the fiscal year ending March 2027, The plan incorporates the assumption that cancellations resulting from the price revision will remain limited, and no customer attrition has occurred at this time, The improvement in gross margin will come from the cumulative effects of the price revision, a higher cloud mix, new plans, and reductions in outsourcing costs through AI, Policies regarding recruitment, M&A, the use of health data, dividends, and market changes |
| New initiatives | Evolving Growbase into a platform centered on the collection, visualization and utilization of wellbeing data, New plans, including Growbase Mentally, are scheduled for release in the second quarter of the fiscal year ending March 2027, Improving the efficiency of the process for digitizing health screening results data through the use of AI, Expanding channels into the mid-sized and small-business market, Considering the continued use and portability of individual-level health data |
Items this document does not state (15)
Net SalesOperating profitOrdinary incomeNet incomeResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeNumber of stores and locationsRisk amount incorporated into the outlookAcquisition of treasury sharesCapital expendituresOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to strengthen communications with investors and fair disclosure. The company states that the answers are based on information available at the time of disclosure and may change in the future.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.